Economic impact of multigene panel testing for hereditary breast and ovarian cancer.

Conclusion: Healthcare utilization and costs were comparable between the SS and panel tests overall and for patients with VUS.
PMID: 33491479 [PubMed - as supplied by publisher]

Source: Journal of Comparative Effectiveness Research - January 26, 2021 Category: General Medicine Tags: J Comp Eff Res Source Type: research